-
2023-507633-21-00
5
Neurological Disease
-
2024-513442-10-00
5
ER positive HER2 negative breast cancer stages I-II
-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2023-505349-26-00
5
Out-of-hospital cardiac arrest.
-
2024-513292-40-00
5
Multiple sclerosis
-
2024-513889-19-00
5
Multiple Myeloma
-
2024-514633-38-00
5
Crohn’s Disease
-
2024-515340-23-00
4
Colon cancer
-
2024-515362-13-00
10
Philadelphia-negative myeloproliferative neoplasms are frequent and ch
-
2024-516257-44-00
4
Multiple myeloma
-
2024-516570-30-00
4
Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
-
2024-517130-17-00
9
FLT3-mutated Acute Myeloid Leukemia
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2024-519753-11-00
4
Resectable borderline pancreatic adenocarcinoma
-
2024-519818-31-01
5
Endometrial Cancer
Advanced, Recurrent, Metastatic, or Primary Unresec
-
2025-520976-25-00
4
Relapsed/refractory multiple myeloma
-
2025-521090-14-00
4
Patients with relapsed/refractory symptomatic multiple myeloma (MM)
-
2025-521199-80-00
4
Patients with previously untreated symptomatic chronic lymphocytic leu
-
2025-521322-14-00
4
Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation,
-
2025-521891-78-00
5
Adult patients with stage IV non squamous non-small cell lung cancer (
-
2025-523683-20-00
4
Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
-
2025-524181-26-00
4
relapsed/refractory multiple myeloma
-
2025-524408-30-01
5
Metastatic hormone-sensitive prostate cancer
-
2025-524573-16-00
6
Crohn's disease